Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples